Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has reported that Veramyst nasal spray has demonstrated significant improvement in the treatment of nasal and ocular allergy symptoms of perennial allergic rhinitis in patients 12 years of age and older.
Subscribe to our email newsletter
Results of this six-week global clinical study showed that Veramyst 110mcg administered once-daily was significantly more effective than placebo in relieving overall nasal allergy symptoms (nasal congestion, rhinorrhea, sneezing and nasal itching), the primary efficacy endpoint.
Veramyst also showed statistically significant improvement in relieving overall eye symptoms (itching/burning, tearing/watering and eye redness), a secondary study endpoint. Veramyst administered once-daily also provided sustained, 24-hour efficacy for both nasal and eye symptoms of perennial allergies.
Eli Meltzer, co-director of the Allergy & Asthma Medical Group and Research Center in San Diego and author of the current study, said: “This study demonstrated the efficacy of Veramyst for patients suffering from both nasal and ocular symptoms all year long, not just during spring and fall allergy seasons. The 24-hour relief from symptoms is also a key patient benefit.”